EQL Pharma AB (publ) (STO:EQL)

Market Cap	750.05M -69.8%
Revenue (ttm)	432.66M +15.8%
Net Income	12.54M -70.9%
EPS	0.42 -70.8%
Shares Out	29.53M
PE Ratio	60.48
Forward PE	31.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	115,789
Open	24.30
Previous Close	24.55
Day's Range	24.30 - 27.20
52-Week Range	23.20 - 98.60
Beta	0.25
Analysts	n/a
Price Target	50.00 (+96.85%)
Earnings Date	Aug 7, 2026

About EQL Pharma AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 60
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EQL

Financial Performance

In fiscal year 2026, EQL Pharma AB's revenue was 432.66 million, an increase of 15.83% compared to the previous year's 373.52 million. Earnings were 12.54 million, a decrease of -70.93%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 16, 2026

Data Sources Report a data error